No Data
No Data
InflaRx's Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights
InflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG Treatment
LifeSci Capital Remains a Hold on InflaRx (IFRX)
InflaRx N.V. Reports Q1 2024 Financial Loss
InflaRx | 6-K: Report of foreign private issuer (related to financial reporting)
InflaRx: Runway to Fund Operations at Least Into 2026 >IFRX
InflaRx: Runway to Fund Operations at Least Into 2026 >IFRX